Tuesday, March 17, 2026

Radioactive Waste from North Korea Could Be Flowing into South Korean Waters

Allegations of untreated radioactive wastewater from North Korea raise concerns in Ganghwa, prompting marine water quality investigations.

U.S. Assistant Secretary Michael DeSombre’s Upcoming Visit to South Korea: What to Expect from the U.S.-Korea Alliance Discussions

U.S. Deputy Assistant Secretary Michael DeSombre visits South Korea to discuss U.S.-South Korea alliance and regional security issues.

Dance, Drama, and Dazzle in BabyMonster’s New Release!

BabyMonster released the full-performance version of "Forever"...

Jin Joong Hwang

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

UK Pours Billions Into Health Tech to Become a Life Sciences Superpower

The UK government aims to lead Europe's life sciences by 2030, investing heavily in health data and regulatory reforms to boost growth.

New Hope for Solid Tumors? Korean Biotech Starts Phase 1 Trial of Targeted Drug

Digmbio secures 12 billion KRW for clinical trials of cancer drug DM5167 and advances treatment for degenerative brain diseases.

AI Search on Safari: Apple Confirms It’s Exploring ChatGPT and Perplexity

Apple is considering integrating AI search engines into Safari, but Google remains the default due to a lucrative contract.

Tumors Shrinking, Hopes Rising: Voronoi’s VRN11 Shows Over 40% Tumor Reduction in Early Lung Cancer Trial

Voronoi's VRN11 shows promising anti-cancer efficacy in early trials, reducing tumors in resistant lung cancer patients without major side effects.

A New Era in Precision Oncology—Lunit Unveils 7 AI-Driven Cancer Studies at AACR 2025

Lunit will present AI biomarker studies at AACR 2025, focusing on rare cancers and improving treatment strategies using AI analysis.

FDA Ruling Paves Way for Pharmacy Substitution of Yuflyma for Humira

Celltrion's Yuflyma receives FDA approval for interchangeability with Humira, boosting market confidence and distribution in the U.S.

Sandoz: Millions of Patients Denied Access to Affordable Enbrel Alternative

Sandoz has filed an antitrust lawsuit against Amgen to challenge patent practices blocking its biosimilar, Erelzi, from market entry.

Europe Moves to Ease Biosimilar Rules, Boosting Asia’s Biopharma Giants

EMA's new guidelines aim to simplify biosimilar development, boosting Samsung Bioepis and Celltrion in Europe's growing market.

Long-Acting HIV Treatment Vocabria + Rekambys Offers New Hope with Just Six Injections a Year

Long-acting HIV treatment Vocabria + Rekambys improves adherence and quality of life, reducing daily pill burden to six injections yearly.

ProGen’s PG-110 Targets Fat Loss Without Muscle Waste—Next-Gen Obesity Drug in Focus

ProGen will present non-clinical results of its obesity drug PG-110 at the ADA conference, targeting muscle preservation and weight loss.

Top News

- Our Sponsors Ad -

Follow us